Related Experiment Video

Updated: Jul 15, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

Targeting Bcl-X(L) for prevention and therapy of skin cancer

Jack Zhang1, G Tim Bowden

  • 1Arizona Cancer Center, University of Arizona, 1515 N. Campbell, Tucson, Arizona 85724, USA.

Molecular Carcinogenesis
|April 20, 2007
PubMed

Insights

Targeting Bcl-X(L), a key regulator of apoptosis, can overcome drug resistance in skin cancer. Inhibiting Bcl-X(L) shows promise for improving chemotherapy efficacy and preventing cancer progression.

Area of Science:

  • Oncology
  • Cell Biology
  • Dermatology

Background:

  • Apoptosis is crucial in skin cancer development.
  • Bcl-X(L) (Bcl-2 extra large) is an antiapoptotic protein that regulates cell survival.
  • Its aberrant expression promotes cancer cell survival and proliferation.

Purpose of the Study:

  • To investigate the role of Bcl-X(L) in skin carcinogenesis.
  • To evaluate Bcl-X(L) as a therapeutic target for overcoming chemotherapy resistance.
  • To explore the potential of Bcl-X(L)-targeting compounds in cancer treatment.

Main Methods:

  • Analysis of Bcl-X(L) expression in skin cancer.
  • Assessment of the impact of Bcl-X(L) overexpression on tumor malignancy and invasion.
  • Evaluation of drug resistance conferred by Bcl-X(L) deregulation.
  • Review of compounds targeting Bcl-X(L) for chemoprevention and chemotherapy.

Main Results:

  • Overexpression of Bcl-X(L) correlates with increased tumor malignancy and invasion.
  • Bcl-X(L) deregulation contributes to drug resistance in cancer cells.
  • Targeting Bcl-X(L) in combination with chemotherapy presents a promising therapeutic strategy.
  • Compounds targeting Bcl-X(L) demonstrate potential in chemoprevention and cancer therapy.

Conclusions:

  • Bcl-X(L) is a critical regulator in skin carcinogenesis and a mediator of chemotherapy resistance.
  • Targeting Bcl-X(L) offers a viable strategy to enhance conventional chemotherapy effectiveness.
  • Further research into Bcl-X(L)-targeting agents could lead to novel cancer treatments.

More Related Videos

Cell Population Analyses During Skin Carcinogenesis06:53

Cell Population Analyses During Skin Carcinogenesis

Published on: August 21, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.